Secretin synthetic human
As of the edition of 20 October 2026, Secretin synthetic human is a protein: marketed, first approved in 2004 (US); acts on SCTR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Protein
- Brand name
- Chirhostim
- First approved
- 9 April 2004 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- ChiRhoClin
- Registered trials
- 9, 4 stopped early
- Disease areas
- Digestive system; Cancer; Hormones; Nutrition and metabolism; Inherited and neonatal; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SCTR | Secretin receptor | P47872 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 2 |
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| ChiRhoClin | Originator and Lead sponsor of trials | 2004 to now |